Regulatory Roundup: Week of October 15, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: Week of October 15, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has opened public consultation on the revised CHMP Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Acute Heart Failure (CHMP/EWP/2986/03 Rev.1).

EMA also released its guideline on medicinal products for the treatment of schizophrenia on Oct. 9, 2012. The guideline describes requirements for the development of medicinal products with regard to study design, patient population, and outcome measures and goes into effect on Apr. 1, 2013.

FDA has collected generic drug information and made it available on their website for industry. The website include guidance document updates, recent meeting minutes, reports, and other relevant information.

Recent guidance documents published by FDA include E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Questions and Answers (R1) (October 2012). A comprehensive list of FDA guidance documents can be found on www.FDA.gov and well as a list of withdrawn guidance documents.

The Orange Book, the Approved Drug Products with Therapeutic Equivalence Evaluations, has been updated with additions and deletions of prescription and OTC products.

The International Conference on Harmonization has released the final meeting report from the latest Global Cooperation Group meeting held in Fukuoka, Japan on June 5, 2012.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here